Brief: Protara Therapeutics Reports Fourth Quarter

Protara Therapeutics

08/03/2023 13:15

March 8 (Reuters) - Protara Therapeutics Inc  TARA.O :
    * PROTARA THERAPEUTICS ANNOUNCES FOURTH QUARTER AND FULL
YEAR 2022
FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
    * Q4 LOSS PER SHARE $3.46
    * SAYS AS OF DECEMBER 31, 2022, CASH, CASH EQUIVALENTS AND
MARKETABLE DEBT SECURITIES TOTALED $102.3 MILLION
    * START UP ACTIVITIES FOR PHASE 2 TRIAL OF TARA-002 IN
LYMPHATIC
MALFORMATIONS UNDERWAY; TRIAL INITIATION EXPECTED 2H23
    * PROTARA THERAPEUTICS - DATA FROM PHASE 1A PORTION OF
ADVANCED-1
TRIAL OF TARA-002 FOR TREATMENT OF NON-MUSCLE INVASIVE BLADDER
CANCER EXPECTED IN 2Q23
    * QTRLY NET LOSS OF $39.0 MILLION, OR $3.46 PER SHARE
    * Q4 EARNINGS PER SHARE VIEW $-0.75 -- REFINITIV IBES DATA

Source text for Eikon:  ID:nGNX7frqsl 
Further company coverage:  TARA.O